Why did it take so long to recall from the market a hip implant after it became apparent that it was causing pain and disability in patients. In a joint investigation, Deborah investigated the regulation of medical devices using the ASR as an exmaple of when things may go wrong.
Over 10 years after the diabetes drug rosiglitazone was approved by regulators, and despite studies on tens of thousands of people, questions remain about its cardiovascular safety. This joint investigation explored the controversies of type 2 diabetes drug, rosiglitazone.
Key scientists advising the World Health Organization on planning for an influenza pandemic had done paid work for pharmaceutical firms that stood to gain from the guidance they were preparing. Deborah investigated conflicts of interest in the WHO and European drug regulators